Brokerages Set Integer Holdings Corporation (NYSE:ITGR) Target Price at $97.00

Shares of Integer Holdings Corporation (NYSE:ITGR) have earned an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $97.00.

A number of research analysts recently issued reports on ITGR shares. Citigroup boosted their target price on shares of Integer from $92.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Truist Financial lifted their price objective on Integer from $97.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Zacks Research raised Integer from a “strong sell” rating to a “hold” rating in a report on Monday, July 20th. Weiss Ratings restated a “hold (c)” rating on shares of Integer in a research note on Thursday, June 18th. Finally, KeyCorp restated an “overweight” rating and issued a $104.00 target price on shares of Integer in a research note on Tuesday, July 21st.

Institutional Investors Weigh In On Integer

Hedge funds have recently bought and sold shares of the stock. Salomon & Ludwin LLC grew its stake in shares of Integer by 46.8% during the 4th quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 118 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Integer by 48.1% during the first quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 117 shares in the last quarter. TD Private Client Wealth LLC boosted its holdings in Integer by 1,037.5% during the fourth quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 415 shares in the last quarter. Parkside Financial Bank & Trust grew its position in Integer by 135.5% during the fourth quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 267 shares during the period. Finally, Arax Advisory Partners grew its position in Integer by 2,489.5% during the fourth quarter. Arax Advisory Partners now owns 492 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 473 shares during the period. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Stock Performance

ITGR opened at $99.67 on Friday. The company has a current ratio of 3.75, a quick ratio of 2.38 and a debt-to-equity ratio of 0.77. Integer has a 12-month low of $62.00 and a 12-month high of $111.99. The firm has a 50 day moving average of $92.66 and a two-hundred day moving average of $88.35. The firm has a market capitalization of $3.38 billion, a PE ratio of 24.85, a P/E/G ratio of 2.35 and a beta of 0.64.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $1.20 EPS for the quarter, missing the consensus estimate of $1.21 by ($0.01). The business had revenue of $439.58 million during the quarter, compared to analysts’ expectations of $426.48 million. Integer had a net margin of 7.64% and a return on equity of 12.83%. The firm’s revenue was up .5% on a year-over-year basis. During the same period last year, the company earned $1.31 earnings per share. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. On average, analysts anticipate that Integer will post 6.04 EPS for the current year.

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.